強強聯合：通和資本+毓承資本=通和毓承

2017年5月18日，中國上海、香港，美國波士頓、舊金山。通和資本與毓承資本今天聯合宣布，兩支團隊將進行合并，組建一個專註於醫療健康領域基金。新投資機構的中文名為"通和毓承"，英文名為6 Dimensions Capital，成為對中美兩地市場均有深度聚焦和覆蓋，並且規模在行業內也是最大之一的投資機構。葯明康德創始人兼董事長、毓承資本創始合伙人李革博士將出任通和毓承的董事長，通和資本創始管理合伙人陳連勇博士將擔任通和毓承的首席執行官。新的通和毓承團隊將由包括7名合伙人，7名投資合伙人在內的24名專業投資人組成。

通和資本成立於2012年，由原富達亞洲成長基金合伙人、醫療健康領域資深投資人陳連勇博士創立，目前管理兩支人民幣基金、一支美元基金合計30億元人民幣規模，已累計投資近20家企業。毓承資本由成立於2011年的原葯明康德風險投資部門獨立而來，目前管理兩支美元基金合計3.5億美元規模，已累計投資近40家企業。合并後的通和毓承管理資金規模達55億人民幣，並將在近期啟動募集新的人民幣和美元基金。

通和與毓承的團隊高度互補。通和在中國本土的風險投資專註更深，而毓承在美國市場的創新型早期投資機會上觸角更廣。雙方的高層管理團隊相信中美同時驅動及規模化將創造更好的投資價值，從而制定了「攜手並進、互惠共贏」的發展戰略。合并後的通和毓承綜合優勢將更為突出，有望成為推動跨太平洋兩岸生命科學及醫療健康領域內創新型投資機會的有力引擎。

對於合并後的通和毓承，李革博士表示：「我非常高興看到兩支團隊合二為一，葯明康德與通和及毓承的投資管理團隊一直以來保持著緊密而高效的合作關係。面對快速發展變革的中國醫療健康行業，和持續以創新為驅動的美國生命科技產業，我認為兩支優秀團隊的合并將能夠更好地貫徹高度差異化的投資策略，進一步鞏固在行業內的領先地位。同時，對於高度依賴人才的風險投資行業來說，這也是一個重要的里程碑事件，新的平台匯聚了更多優秀的投資人，對於我們發掘更多優質項目和為被投企業提供更多價值輸出都有重要的意義」。

通和毓承首席執行官陳連勇博士表示：「通和與毓承管理合伙人之間有著長期的精誠合作的歷史並取得了豐碩的成果。雙方團隊都懷有同樣的使命願景，並已經通過共同的項目投資建立起了互信互助的工作模式，這為兩個團隊的快速融合奠定了堅實的基礎。。我相信在更高的起點上，通和毓承會充分發揮資本和資源的彙集效應，進一步提高我們拓展項目和控制風險的能力，不僅能為投資人繼續創造優質的回報，也會為中國醫療健康產業的發展貢獻積極的力量」。

Frontline BioVentures and WuXi Healthcare Ventures Join Forces to Form 6 Dimensions Capital, a leading China and US Focused Investment Group Specializing in Healthcare and Life Sciences

18th May, 2017, Shanghai, Hong Kong, Boston, San Francisco. Frontline BioVentures (Frontline) and WuXi Healthcare Ventures (WuXi Ventures) jointly announced today a merger to form one healthcare investment group named 6 Dimensions Capital. It will become one of the largest healthcare focused investment firms with an in-depth focus and extensive coverage across China and the US. Dr. Ge Li, the founder, Chairman and CEO of WuXi AppTec, and a Founding Partner of WuXi Healthcare Ventures, will become 6 Dimensions Capital』s Chairman of the Board. Dr. Leon Chen, the Founder and Managing Partner of Frontline BioVentures, will become 6 Dimensions Capital』s CEO. The new investment team will consist of 24 investment professionals, including 7 Partners and 7 Venture Partners.

Frontline was founded in 2012 by seasoned life sciences venture capitalist, ex-Partner of Fidelity Growth Partners-Asia, Dr. Leon Chen. Currently, Frontline manages two RMB-denominated funds and one USD-denominated fund, with a combined AUM of RMB 3 billion, and has cultivated a portfolio of close to 20 companies. A spin-off from WuXi AppTec』s corporate venture department established in 2011, WuXi Ventures currently manages two USD-denominated funds with a combined AUM of USD 350 million and has invested in a portfolio of close to 40 companies. The resulting 6 Dimensions Capital will be managing a combined AUM of RMB 5.5 billion, or close to USD 800 million, and plans to start raising new RMB and USD-denominated funds in the near future.

The teams are highly complementary to each other. Frontline has a more established venture investment exposure in China and WuXi Ventures has a clear advantage with its access to innovative startups in the US. The benefit of a combined force motivated top management to come together. The merger creates a powerhouse to fund innovation in an optimal position to capture the biggest value appreciation on both sides of the Pacific.

Commenting on the formation of 6 Dimensions Capital, Dr. Ge Li said, 「I am very pleased to see that the two teams have joined forces. WuXi AppTec, Frontline BioVentures, and WuXi Healthcare Ventures』 management teams have an established, close, and efficient collaborative relationship. Facing the rapidly growing and evolving healthcare landscape in China, and a promisingly continued innovation-driven environment in the US, I believe the consolidation of the two distinguished teams enables the firm』s better execution of highly differentiated investment strategies to further solidify our leadership in the industry. Meanwhile, this is a major milestone for us, because fundamentally venture capital is about human capital. This new platform brings together more exceptional investment professionals, empowering us to discover and identify high-quality deals and to create value with and from portfolio companies from different dimensions.」

Dr. Leon Chen said, 「the managing partners of both firms have a long history of close collaborations with successful outcomes. We share the same vision, have an established chemistry, and have a mutual trust in working together through previous investment opportunities. This history has laid a solid foundation for a fast integration. I believe at this new and elevated starting point, 6 Dimensions Capital will be equipped with economies of scale in deploying capital and resources, and further strengthen our deal sourcing and risk control capabilities. 6 Dimensions Capital aims to not only generate even larger value for our investors, but also favorably contribute to healthcare industry development in China and in the US at multiple dimensions.」

喜歡這篇文章嗎？立刻分享出去讓更多人知道吧！